University of Oxford — developed a vaccine candidate for the Bundibugyo Ebola strain with Serum Institute of India and CEPI using viral vector technology.
… The trials are being coordinated with partners in the Democratic Republic of Congo, Uganda, and international research institutions, including the University of Oxford. …
… In response, the Serum Institute of India has partnered with the University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of a vaccine candidate known as ChAdOx1 BDBV. …
… Another vaccine candidate receiving CEPI funding was developed on the University of Oxford's ChAdOx1 platform, which also underpinned AstraZeneca's Covid vaccine. …
… V.S Naipaul, who went to University of Oxford in 1950 on a Trinidad government scholarship and later became a British citizen, once told an Indian newspaper he did not consider himself Indian because, according to him, “they do not understand literature there.”So, when the announ …
… Juma holds a PhD from the University of Oxford, where she also earned a Certificate in Refugee Studies, in addition to Master’s and Bachelor’s degrees in Government and Public Administration from the University of Nairobi. …
The United States has provided doses of an experimental antibody drug developed by Mapp Biopharmaceutical to support clinical trials in the Democratic Republic of Congo's Ebola outbreak, marking a shift from prior US-only availability. The move comes as health authorities work to contain a rapidly spreading Bundibugyo strain outbreak that has recorded more than 1,000 cases and over 250 deaths.
The United States has provided doses of an experimental antibody drug developed by Mapp Biopharmaceutical to support clinical trials in the Democratic Republic of Congo's Ebola outbreak, marking a shift from prior US-only availability. The move comes as health authorities work to contain a rapidly spreading Bundibugyo strain outbreak that has recorded more than 1,000 cases and over 250 deaths.
The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for clinical trials in the Democratic Republic of Congo's Bundibugyo Ebola outbreak, which has caused over 1,000 cases and more than 250 deaths. The trial data could inform future U.S. regulatory review and potential approval.
The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for use in clinical trials and compassionate use to fight an Ebola outbreak in Democratic Republic of Congo. The Bundibugyo strain has caused more than 1,000 cases in Congo and more than 250 deaths, with a handful of cases also reported in Uganda.
More than 875 cases of the Bundibugyo Ebola strain have been confirmed, including 202 deaths, in a little over a month across DR Congo and Uganda, with no currently available vaccines or treatments for this strain. Scientists and pharmaceutical companies are racing to develop new vaccines and treatments, with the WHO calling an rVSV-based vaccine candidate "most promising" and estimating it will take seven to nine months before human testing can begin.
A Reuters Institute report based on surveys of almost 100,000 people across 48 countries found that 54 percent of respondents got news from social media or video platforms in the week before the survey, exceeding the 52 percent who referenced TV news. This marks the first year social media and video network consumption is ahead of other news sources globally.
The Serum Institute of India is leading development of a vaccine targeting the Bundibugyo strain of Ebola in response to an outbreak in the Democratic Republic of Congo first reported in May 2026, which the WHO has declared a Public Health Emergency of International Concern. The vaccine, developed with the University of Oxford and CEPI, uses the same viral vector technology as the Oxford-AstraZeneca COVID-19 vaccine and trial doses are expected in the coming months.
Non-profit organisations announced Monday they are ramping up efforts to develop a vaccine for the Bundibugyo strain of Ebola, which has caused an outbreak in the Democratic Republic of Congo and Uganda with nearly 250 suspected deaths and more than 1,100 infections. The strain, for which there are no approved vaccines or treatments, has prompted a race to rapidly develop, manufacture and test a vaccine in clinical trials in the affected region.
The 2001 Nobel Prize in Literature award to V.S. Naipaul prompted backlash from the literary community, including Nobel laureate Wole Soyinka, who objected to what they saw as the committee endorsing Naipaul's contemptuous attitude toward his country of origin, Trinidad and Tobago. Naipaul's work portrays broken societies and fractured systems, including depictions of education as uncertain and arbitrary.
Monica Juma of Kenya has assumed office in Vienna as Director-General of the UN Office at Vienna and Executive Director of the UN Office on Drugs and Crime (UNODC), following her appointment by UN Secretary-General António Guterres. She previously served as Kenya's first National Security Adviser and held Cabinet Secretary positions in Energy, Defence, and other strategic ministries.
Kenyan diplomat Dr. Monica Juma has officially assumed office as Director-General of the United Nations Office at Vienna and Executive Director of the United Nations Office on Drugs and Crime, with the rank of Under-Secretary-General. She expressed commitment to leading the UN's work in addressing drugs, organized crime, corruption, and terrorism.